Analyze Diet

Topic:Immunization

Immunization in horses involves the administration of vaccines to stimulate an immune response, thereby providing protection against specific infectious diseases. Vaccines commonly used in equine medicine include those for equine influenza, tetanus, and West Nile virus. The process of immunization aims to prepare the horse's immune system to recognize and combat pathogens upon exposure. Vaccination schedules and protocols may vary based on factors such as age, health status, and regional disease prevalence. This page compiles peer-reviewed research studies and scholarly articles that explore the mechanisms, efficacy, and considerations of immunization practices in equine health.
Behavioral responses to two intranasal vaccine applicators in horses and ponies.
Journal of the American Veterinary Medical Association    May 24, 2005   Volume 226, Issue 10 1689-1693 doi: 10.2460/javma.2005.226.1689
Grogan EH, McDonnell SM.To evaluate behavioral compliance of horses and ponies with simulated intranasal vaccination and assess development of generalized aversion to veterinary manipulations. Methods: Clinical trial. Methods: 28 light horse mares, 3 pony geldings, 2 light horse stallions, and 3 pony stallions that had a history of compliance with veterinary procedures. Methods: Behavioral compliance with 2 intranasal vaccine applicators was assessed. Compliance with standard physical examination procedures was assessed before and after a single experience with either of the applicators or a control manipulation to e...
Genetic immunization with codon-optimized equine infectious anemia virus (EIAV) surface unit (SU) envelope protein gene sequences stimulates immune responses in ponies.
Veterinary microbiology    May 12, 2005   Volume 108, Issue 1-2 23-37 doi: 10.1016/j.vetmic.2005.04.004
Cook RF, Cook SJ, Bolin PS, Howe LJ, Zhou W, Montelaro RC, Issel CJ.In the context of DNA vaccines the native equine infectious anemia virus (EIAV)-envelope gene has proven to be an extremely weak immunogen in horses probably because the RNA transcripts are poorly expressed owing to an unusual codon-usage bias, the possession of multiple RNA splice sites and potential adenosine-rich RNA instability elements. To overcome these problems a synthetic version of sequences encoding the EIAV surface unit (SU) envelope glycoprotein was produced (SYNSU) in which the codon-usage bias was modified to conform to that of highly expressed horse and human genes. In transfect...
Potential of equine herpesvirus 1 as a vector for immunization.
Journal of virology    April 14, 2005   Volume 79, Issue 9 5445-5454 doi: 10.1128/JVI.79.9.5445-5454.2005
Trapp S, von Einem J, Hofmann H, Köstler J, Wild J, Wagner R, Beer M, Osterrieder N.Key problems using viral vectors for vaccination and gene therapy are antivector immunity, low transduction efficiencies, acute toxicity, and limited capacity to package foreign genetic information. It could be demonstrated that animal and human cells were efficiently transduced with equine herpesvirus 1 (EHV-1) reconstituted from viral DNA maintained and manipulated in Escherichia coli. Between 13 and 23% of primary human CD3+, CD4+, CD8+, CD11b+, and CD19+ cells and more than 70% of CD4+ MT4 cells or various human tumor cell lines (MeWo, Huh7, HeLa, 293T, or H1299) could be transduced with o...
Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom.
The Veterinary record    April 9, 2005   Volume 156, Issue 12 367-371 doi: 10.1136/vr.156.12.367
Edlund Toulemonde C, Daly J, Sindle T, Guigal PM, Audonnet JC, Minke JM.Fifteen influenza-naive Welsh mountain ponies were randomly assigned to three groups of five. A single dose of a recombinant ALVAC vaccine was administered intramuscularly to five of the ponies, two doses, administered five weeks apart, were administered to five, and the other five served as unvaccinated, challenge controls. Two weeks after the completion of the vaccination programme, the ponies were all challenged by exposure to an aerosol of influenza virus A/eq/Newmarket/5/03. Their clinical signs were scored daily for 14 days according to a standardised scoring protocol, and nasal swabs we...
A recombinant envelope protein vaccine against West Nile virus.
Vaccine    April 6, 2005   Volume 23, Issue 30 3915-3924 doi: 10.1016/j.vaccine.2005.03.006
Ledizet M, Kar K, Foellmer HG, Wang T, Bushmich SL, Anderson JF, Fikrig E, Koski RA.West Nile (WN) virus is a flavivirus that first appeared in North America in 1999. Since then, more than 600 human deaths and 22,000 equine infections have been attributed to the virus in the United States. We expressed a truncated form of WN virus envelope (E) protein in Drosophila S2 cells. This soluble recombinant E protein was recognized by antibodies from naturally infected horses, indicating that it contains native epitopes. Mice and horses produced high-titer antibodies when immunized with recombinant E protein combined with aluminum hydroxide. Immunized mice were resistant to challenge...
Effects of GnRH immunization in sexually mature pony stallions.
Animal reproduction science    March 16, 2005   Volume 86, Issue 3-4 247-259 doi: 10.1016/j.anireprosci.2004.07.010
Turkstra JA, van der Meer FJ, Knaap J, Rottier PJ, Teerds KJ, Colenbrander B, Meloen RH.Immunization against gonadotrophin releasing hormone (GnRH) was studied as an alternative for the commonly used surgical castration in stallions. Two GnRH vaccines comprising non-mineral oil adjuvants were evaluated for their potential to induce high antibody titers directed against GnRH and subsequent effects on reproductive characteristics. Twelve sexually mature male hemicastrated Shetland ponies were assigned to three groups. Group 1 and 2 were injected with 1mg peptide equivalent of G6k-GnRH-tandem-dimer conjugated to ovalbumin (OVA) in CoVaccine HT adjuvant (GnRH/CoVaccine) and in Carbop...
The improvement of the therapeutic anti-Lachesis muta serum production in horses.
Toxicon : official journal of the International Society on Toxinology    March 1, 2005   Volume 45, Issue 4 467-473 doi: 10.1016/j.toxicon.2004.12.006
Stephano MA, Guidolin R, Higashi HG, Tambourgi DV, Sant'Anna OA.The main features associated with pit viper envenomations include the intense local lesions such as oedema, necrosis, acute renal failure and other effects. The severity of these reactions to snakebite depends on the degree of envenomation. Lachesis muta venom (LMV) has weak lethal activity, but due to the large amount often inoculated, the effects are extremely severe and demand anti-venom with a high neutralizing capacity. LMV had the lowest neutralizing antibody induction capacity in horses when compared with that of other venoms. For example, Bothrops anti-venom serum neutralizes 180 times...
Assessment in mice of vapA-DNA vaccination against Rhodococcus equi infection.
Veterinary immunology and immunopathology    March 1, 2005   Volume 104, Issue 3-4 215-225 doi: 10.1016/j.vetimm.2004.12.006
Haghighi HR, Prescott JF.There is a need to produce a vaccine against Rhodococcus equi pneumonia in foals in which immunity against infection is largely based on a type 1, cell-mediated, immune response. The VapA protein of the virulence plasmid of R. equi is highly immunogenic. To assess the potential of vapA-DNA to produce immunity, C57BL/6 and BALB/c mice were immunized with a DNA vaccine constructed from vapA incorporated into pcDNA3.1. The plasmid construct expressed VapA in a COS-7 cell line. Intramuscular immunization of mice resulted in enhanced clearance of R. equi from the liver of intravenously challenged m...
The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine.
Veterinary therapeutics : research in applied veterinary medicine    February 19, 2005   Volume 5, Issue 4 251-257 
Grosenbaugh DA, Backus CS, Karaca K, Minke JM, Nordgren RM.A new recombinant West Nile virus (WNV) vaccine has been licensed for use in horses. Prior to the availability of the recombinant vaccine in 2004, the only equine WNV vaccine available on the market had been an inactivated vaccine. Since the recombinant vaccine only expresses selected viral genes, the question could be posed as to whether a single dose of the recombinant vaccine would be effective in producing an anamnestic serologic response in horses previously vaccinated with an inactivated WNV vaccine. In this study we demonstrate that vaccination of horses with a canarypox-vectored recomb...
Immune response to vaccines based upon the VapA protein of the horse pathogen, Rhodococcus equi, in a murine model.
International journal of medical microbiology : IJMM    February 18, 2005   Volume 294, Issue 7 437-445 doi: 10.1016/j.ijmm.2004.09.011
Vanniasinkam T, Barton MD, Heuzenroeder MW.Rhodococcus equi is a significant pathogen in foals predominantly causing a pyogranulomatous bronchopneumonia. Many vaccine candidates have been tested for the prevention of R. equi disease in foals. However, none of these have been developed for widespread commercial use. Previous studies have shown that a Th1 immune response is imperative for the protection of foals against R. equi disease. In this study a DNA and a protein vaccine based upon the well-characterised R. equi virulence-associated protein VapA were developed. The vaccines were tested in the BALB/c murine model and the results sh...
Persistence of anti-zonae pellucidae antibodies following a single inoculation of porcine zonae pellucidae in the domestic equine.
Reproduction (Cambridge, England)    February 8, 2005   Volume 129, Issue 2 181-190 doi: 10.1530/rep.1.00168
Liu IK, Turner JW, Van Leeuwen EM, Flanagan DR, Hedrick JL, Murata K, Lane VM, Morales-Levy MP.In this study of equids, we investigated the antibody response and the effect on the estrous cycle following a single inoculation of porcine zonae pellucidae (pZP) employing controlled-release methodology. We also investigated the use of two different water-soluble adjuvants as an alternative to oil-based adjuvants. Twenty-seven domestic mares were inoculated with various formulations of pZP and adjuvant. We showed that the anti-pZP antibodies generated as a result of the inoculations persisted for at least 43 weeks (length of the study). Of the various formulations used in the study, pZP and ...
Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses.
American journal of veterinary research    November 30, 2004   Volume 65, Issue 11 1459-1462 doi: 10.2460/ajvr.2004.65.1459
Siger L, Bowen RA, Karaca K, Murray MJ, Gordy PW, Loosmore SM, Audonnet JC, Nordgren RM, Minke JM.To determine the onset of immunity after IM administration of a single dose of a recombinant canarypox virus vaccine against West Nile virus (WNV) in horses in a blind challenge trial. Methods: 20 mixed-breed horses. Methods: Horses with no prior exposure to WNV were randomly assigned to 1 of 2 groups (10 horses/group). In 1 group, a recombinant canarypox virus vaccine against WNV was administered to each horse once (day 0). The other 10 control horses were untreated. On day 26, 9 treated and 10 control horses were challenged via the bites of mosquitoes (Aedes albopictus) infected with WNV. Cl...
Rescue of disabled infectious single-cycle (DISC) equine arteritis virus by using complementing cell lines that express minor structural glycoproteins.
The Journal of general virology    November 24, 2004   Volume 85, Issue Pt 12 3709-3714 doi: 10.1099/vir.0.80443-0
Zevenhoven-Dobbe JC, Greve S, van Tol H, Spaan WJM, Snijder EJ.Equine arteritis virus (EAV) contains seven structural proteins that are all required to produce infectious progeny. Alphavirus-based expression vectors have been generated for each of these proteins to explore the possibilities for their constitutive expression in cell lines. This approach was successful for minor glycoproteins GP(2b), GP(3) and GP(4) and for the E protein. Subsequently, it was demonstrated that cell lines expressing these proteins could rescue EAV mutants that were disabled in the expression of the corresponding gene, resulting in the production of virus particles carrying t...
Fc receptors in livestock species.
Veterinary immunology and immunopathology    November 16, 2004   Volume 102, Issue 4 351-362 doi: 10.1016/j.vetimm.2004.06.008
Kacskovics I.Many of the receptors for the Fc domain of immunoglobulins in cattle, sheep, pigs and horses have been cloned and characterized recently. This review summarises recent developments and relates them to the current understanding of the primary structure, cellular specificity and binding properties of Fc receptors (FcRs). Although there is an obvious overall similarity to their human and mouse counterparts, some Fc receptors in domestic animals are unusual, perhaps most notably the bovine Fcgamma2R, which although related to other mammalian FcgammaRs, belongs to a novel gene family and the porcin...
Foal IgG and opsonizing anti-Rhodococcus equi antibodies after immunization of pregnant mares with a protective VapA candidate vaccine.
Veterinary microbiology    November 9, 2004   Volume 104, Issue 1-2 73-81 doi: 10.1016/j.vetmic.2004.09.006
Cauchard J, Sevin C, Ballet JJ, Taouji S.The aim of this study was to evaluate serum IgG antibody levels and opsonizing activity in foals from pregnant mares immunized with either proteins from an R. equi strain containing virulence-associated protein A (VapA), an immunodominant surface-expressed lipoprotein encoded by a virulence plasmid crucial for virulence in foals, or a whole killed virulent R. equi preparation. Forty-eight pregnant mares were distributed into three groups, i.e. 24 immunized with R. equi VapA protein antigen associated with a water-based nanoparticle adjuvant (Montanide IMS 3012), 8 immunized with whole killed R...
Equine papillomavirus type 1: complete nucleotide sequence and characterization of recombinant virus-like particles composed of the EcPV-1 L1 major capsid protein.
Biochemical and biophysical research communications    October 16, 2004   Volume 324, Issue 3 1108-1115 doi: 10.1016/j.bbrc.2004.09.154
Ghim SJ, Rector A, Delius H, Sundberg JP, Jenson AB, Van Ranst M.Equus caballus papillomavirus type 1 (EcPV-1) was isolated from a cutaneous papilloma, the most common neoplasm in horses. The complete EcPV-1 nucleotide sequence and genomic organization were determined. Phylogenetic analysis showed that EcPV-1 is a close-to-root papillomavirus, with only distant relationships to the fibropapillomaviruses and the benign cutaneous papillomaviruses. To produce EcPV-1 virus-like particles (VLPs), the EcPV-1 L1 major capsid protein was expressed in insect cells using a recombinant baculovirus vector. The self-assembled EcPV-1 VLPs were morphologically indistingui...
Recombinant vesicular stomatitis (Indiana) virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host.
Vaccine    September 15, 2004   Volume 22, Issue 29-30 4035-4043 doi: 10.1016/j.vaccine.2004.03.065
Martinez I, Barrera JC, Rodriguez LL, Wertz GW.Vesicular stomatitis virus (VSV) is the most common cause of vesicular disease outbreaks in livestock throughout the Western Hemisphere. Two major serotypes, Indiana and New Jersey, cause epidemic disease in pigs, cattle, and horses. We generated recombinant viruses derived from the Indiana serotype genome that were engineered to contain and express: (1) a single copy of the glycoprotein gene from the Indiana serotype (VSIV-GI); (2) a single copy of the glycoprotein gene from the New Jersey serotype (VSIV-GNJ); or (3) two copies of the glycoprotein gene, one from each of the two major VSV sero...
Humoral response to West Nile virus vaccination in alpacas and llamas.
Journal of the American Veterinary Medical Association    August 27, 2004   Volume 225, Issue 3 414-416 doi: 10.2460/javma.2004.225.414
Kutzler MA, Baker RJ, Mattson DE.To determine humoral responses to an equine West Nile virus (WNV) vaccine in healthy alpacas and llamas and compare responses in alpacas and llamas with responses in horses. Methods: Clinical trial. Methods: 28 alpacas, 56 llamas, and 16 horses. Methods: Horses received 2 vaccinations at 4-week intervals, and alpacas and llamas received 3 vaccinations at 3-week intervals. Fifty-five llamas received a fourth vaccination 3 weeks after the third. Blood samples were collected immediately prior to each vaccination, 3 weeks after the last vaccination for alpacas and llamas, and 4 weeks after the las...
West Nile virus vaccines.
Expert opinion on biological therapy    July 23, 2004   Volume 4, Issue 8 1295-1305 doi: 10.1517/14712598.4.8.1295
Hall RA, Khromykh AA.West Nile virus (WNV) is a mosquito-borne flavivirus that is emerging as a global pathogen. In the last decade, virulent strains of the virus have been associated with significant outbreaks of human and animal disease in Europe, the Middle East and North America. Efforts to develop human and veterinary vaccines have taken both traditional and novel approaches. A formalin-inactivated whole virus vaccine has been approved for use in horses. DNA vaccines coding for the structural WNV proteins have also been assessed for veterinary use and have been found to be protective in mice, horses and birds...
Efficacy of a live equine herpesvirus-1 (EHV-1) strain C147 vaccine in foals with maternally-derived antibody: protection against EHV-1 infection.
Equine veterinary journal    July 16, 2004   Volume 36, Issue 5 447-451 doi: 10.2746/0425164044868332
Patel JR, Didlick S, Bateman H.Currently, there is no recommended immunoprophylaxis against febrile respiratory diseases due to equine herpesvirus-1 (EHV-1) and -4 (EHV-4) in horses below age 5-6 months. This is because of interference by maternally-derived antibody (MDA) of vaccines. Objective: Unweaned equine foals are an important reservoir of EHV-1 transmission; therefore, we experimentally assessed the efficacy of a live EHV-1 vaccine in foals age 1.4-3.5 months with MDA. Methods: Following vaccination and challenge, parameters assessed were virus shedding in nasal mucus, leucocyte-associated viraemia, circulating viru...
DNA vaccines–back in the saddle again?
Nature biotechnology    July 2, 2004   Volume 22, Issue 7 799-801 doi: 10.1038/nbt0704-799
Powell K.A promising new horse vaccine may reignite enthusiasm for DNA vaccine technology in designing prophylactics against infectious disease. Kendall Powell reports.
The uveitogenic potential of retinal S-antigen in horses.
Investigative ophthalmology & visual science    June 30, 2004   Volume 45, Issue 7 2286-2292 doi: 10.1167/iovs.03-1226
Deeg CA, Reese S, Gerhards H, Wildner G, Kaspers B.To investigate the uveitogenic potential of retinal S-antigen (S-Ag) in horses. Methods: Horses were immunized subcutaneously with S-Ag or BSA as control antigen, emulsified in complete Freund's adjuvant. Simultaneously, Bordetella pertussis was given intravenously. Antigen specific T- and B-cell responses were analyzed in a 3-day interval. Disease development was judged clinically and histopathologically. Two identical booster immunizations were given every 4 weeks to test induction of recurrences. Results: T- and B-cell responses specific for S-Ag were observed in all immunized horses but we...
[Combination immunization with EIAV Env protein expressed by recombinant baculovirus and recombinant vaccinia virus containing env gene]. Dai CM, Zhang XY, Zhang RR, Shao YM, Shen RX.To develop a novel vaccine candidate of Equine infectious anemia virus(EIAV). Methods: env genes of EIAV Chinese donkey leukocyte attenuated strain (EIAV DLV) and its parental virus strain (EIAV LN) were expressed using the BAC-To-BAC system, and Env proteins were confirmed by SDS-PAGE and Western blot. BALB/c mice were immunized with recombinant vaccinia viruses containing env genes of EIAV alone or boosted with Env proteins expressed by recombinant baculovirus. Both protective humoral and cellular immune responses were detected. Results: Recombinant baculovirus could express complete Env pro...
Recombinant Streptococcus equi proteins protect mice in challenge experiments and induce immune response in horses.
Infection and immunity    May 25, 2004   Volume 72, Issue 6 3228-3236 doi: 10.1128/IAI.72.6.3228-3236.2004
Flock M, Jacobsson K, Frykberg L, Hirst TR, Franklin A, Guss B, Flock JI.Horses that have undergone infection caused by Streptococcus equi subspecies equi (strangles) were found to have significantly increased serum antibody titers against three previously characterized proteins, FNZ (cell surface-bound fibronectin binding protein), SFS (secreted fibronectin binding protein), and EAG (alpha2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein) from S. equi. To assess the protective efficacy of vaccination with these three proteins, a mouse model of equine strangles was utilized. Parts of the three recombinant proteins were used to immunize mice, eith...
Evaluation of immune responses in horses immunized using a killed Sarcocystis neurona vaccine.
Veterinary therapeutics : research in applied veterinary medicine    May 20, 2004   Volume 5, Issue 1 34-42 
Marsh AE, Lakritz J, Johnson PJ, Miller MA, Chiang YW, Chu HJ.Clinically normal horses developed cellular immunity to Sarcocystis neurona following IM vaccination with a commercial killed S. neurona vaccine, as indicated by the development of measurable anti-S. neurona IgG antibodies and additional intradermal skin testing. Large-scale independent assessments of the vaccine's performance and safety are in progress under field conditions. The next step in the evaluation of this vaccine would be to attempt experimental challenge after a reproducible reliable equine model of S. neurona encephalitis has been established that allows for reisolation of the pat...
Equine seminal plasma reduces sperm binding to polymorphonuclear neutrophils (PMNs) and improves the fertility of fresh semen inseminated into inflamed uteri.
Reproduction (Cambridge, England)    May 7, 2004   Volume 127, Issue 5 593-600 doi: 10.1530/rep.1.00096
Alghamdi AS, Foster DN, Troedsson MH.Seminal plasma (SP) is known to have immunosuppressive properties in several species. Equine SP has been reported to reduce or inhibit chemotaxis, phagocytosis and complement activity in vitro. The type and amount of the SP component that suppresses sperm-polymorphonuclear neutrophil (PMN) binding in vitro was determined, and the effect of such suppression on the fertility of mares inseminated in the presence of uterine inflammation, was analyzed. Sperm cells were suspended in either SP, semen extender or a mixture of both, and each was mixed with PMN-rich uterine secretions collected at 12 h ...
Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge.
Archives of virology. Supplementum    May 4, 2004   Issue 18 221-230 doi: 10.1007/978-3-7091-0572-6_20
Minke JM, Siger L, Karaca K, Austgen L, Gordy P, Bowen R, Renshaw RW, Loosmore S, Audonnet JC, Nordgren B.An ALVAC (canarypoxvirus)-based recombinant (vCP2017) expressing the prM and E genes derived from a 1999 New York isolate of West Nile virus (WNV) was constructed and assessed for its protective efficacy in horses in two different experiments. In the first trial, a dose titration study was conducted to evaluate both serum neutralising antibody responses to WNV and duration of immunity. In the second trial the onset of protection was determined. Twenty-eight adult horses received two doses of vCP2017 administered intramuscularly at 5-week intervals and sixteen horses comprised age-matched non-v...
Prospects for vaccination against equine grass sickness.
Equine veterinary journal    March 25, 2004   Volume 36, Issue 2 186-191 doi: 10.2746/0425164044868710
Hedderson EJ, Newton JR.Their is both historical and modern scientific evidence to support the hypothesis that equine grass sickness (EC'S) is caused by a toxico-infectious form of botulism involving a Clostridium botulism type C toxin 1114 is produced locally within the gastrointestinal tract of affected horses (Toc her et al. 1923: Tneher 1924: Hunter a aL 1999: Hunter and anion 2001: McCarthy 2002: McCarthy a aL 201)4a1. This report concerns a meeting convened to review the current state of knowledge and possible strategies for vaccination against EGS. including historical. clinical and pathological aspects of the...
Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination.
Veterinary immunology and immunopathology    March 11, 2004   Volume 98, Issue 3-4 127-136 doi: 10.1016/j.vetimm.2003.11.004
Breathnach CC, Rudersdorf R, Lunn DP.Recombinant modified vaccinia Ankara (MVA) vectors expressing equine influenza virus genes were constructed and evaluated for use in equine vaccination. Two strains of recombinant MVA, expressing either hemagglutinin (HA) or nucleoprotein (NP) genes were constructed. Each influenza virus gene was cloned from A/equine/Kentucky/1/81 (Eq/Ky) into an MVA construction plasmid, and was introduced to the deletion III locus of the wild type MVA genome by homologous recombination. Recombinant viruses were plaque purified, and antigen expression was confirmed by immunostaining. Two ponies were primed by...
Immunogenecity of synthetic peptides representing linear B-cell epitopes of VapA of Rhodococcus equi.
Vaccine    March 9, 2004   Volume 22, Issue 9-10 1114-1123 doi: 10.1016/j.vaccine.2003.10.006
Taouji S, Nomura I, Giguère S, Tomomitsu S, Kakuda T, Ganne V, Takaï S.Amino acid 65-78 of membrane protein VapA of the facultative intracellular Rhodococcus equi contained an immunodominant N-terminal B-cell epitope (N15Y peptide). Safety and immunogenecity of a synthetic peptide consisting of the amino acid 65-78 of VapA (peptide N15Y) were evaluated first in mice and in healthy adult horses. A single dose of a peptide-VapA vaccine induced and only in presence of adjuvant, specific IgG antibodies in sera of mice. After challenge with virulent R. equi 3 weeks after immunization, tissue clearance was more delayed in immunized mice than in control mice. An antibod...
1 13 14 15 16 17 31